Welcome to our dedicated page for Pharvaris N.V. SEC filings (Ticker: PHVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pharvaris N.V. (PHVS) SEC filings page on Stock Titan brings together the company’s U.S. regulatory disclosures as a foreign private issuer listed on Nasdaq. Pharvaris files annual reports on Form 20-F and furnishes interim updates on Form 6-K under the Securities Exchange Act of 1934, providing investors with information on its late-stage biopharmaceutical operations and capital markets activity.
Through Forms 6-K, Pharvaris furnishes press releases on financial results and business updates, including quarterly IFRS-based financial statements, management’s discussion and analysis, and details on cash runway and research and development spending. These filings also cover outcomes of the company’s Annual General Meeting of Shareholders, auditor appointments, and board-related matters.
Filings related to capital raising and securities include descriptions of underwritten public offerings of ordinary shares and pre-funded warrants, underwriting agreements, pre-funded warrant terms, and associated legal opinions. For example, Pharvaris has used an effective shelf registration statement on Form F-3 and Form F-3ASR to register offerings that fund late-stage clinical programs, commercialization preparation, and general corporate purposes.
For its core therapeutic focus, investors can use Pharvaris filings alongside AI-powered summaries to understand disclosures around clinical development of deucrictibant for hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). While detailed clinical data are often first released via press releases, they are also referenced in 6-K reports that are incorporated by reference into the company’s registration statements.
Stock Titan’s tools can help interpret these documents by highlighting key points from lengthy exhibits, such as interim financial statements, registration rights agreements, and offering documentation. Real-time updates from EDGAR, combined with AI-generated explanations, allow users to quickly review new Pharvaris filings, track how the company finances its late-stage pipeline, and monitor changes in its registered securities.
Pharvaris N.V. director Johannes Schikan reported open-market sales of 7,100 shares of Common Stock in two transactions. He sold 7,000 shares on April 22, 2026 at $30.0541 per share and 100 shares on April 23, 2026 at $30.03 per share, under a pre-planned Rule 10b5-1 trading plan. Following these sales, he directly holds 388,067 Pharvaris shares.
Pharvaris N.V. Chief Early Development officer Anne Lesage reported a combination of stock option exercises and share sales in Pharvaris common stock. On April 22–23, 2026, she exercised 7,600 stock options and sold 14,700 common shares in open-market transactions at prices around $30 per share, as part of a Rule 10b5-1 trading plan.
Following these transactions, Lesage holds 56,450 Pharvaris shares directly and 156,869 shares indirectly through GrayMatters Consulting B.V. The exercised options carried strike prices of $8.05 and $2.59 and were originally subject to multi-year vesting schedules.
Pharvaris N.V. Chief Medical Officer Lu Peng executed a small, pre-planned option exercise-and-sell transaction under a Rule 10b5-1 trading plan. On April 22–23, 2026, Peng exercised options to acquire 7,101 shares of common stock at $2.59 per share and sold the same 7,101 shares in open-market transactions around $30 per share.
After these trades, Peng directly holds 66,083 shares of common stock and 106,207 stock options expiring in 2030. The filing characterizes the activity as a scheduled transaction pursuant to a Rule 10b5-1 trading plan, indicating it was arranged in advance rather than timed opportunistically.
Pharvaris N.V. Chief Medical Officer Lu Peng reported a routine tax-related share withholding. On April 16, 2026, 226 common shares were disposed of at a fair market value of $28.78 per share to satisfy tax withholding obligations from restricted stock units that vested on April 11 and April 12, 2026. After this non‑market transaction, Lu Peng directly held 66,083 common shares.
Pharvaris N.V. Chief Executive Officer Berndt Modig reported a small open-market sale of company stock. On April 16, 2026, he sold 2,292 shares of Pharvaris common stock at a weighted average price of $28.6032 per share in a series of trades executed under a Rule 10b5-1 trading plan. These sales involved shares that include stock previously acquired upon vesting of restricted stock units. After the sale, he directly owns 139,792 shares of common stock and also has an indirect holding of 950,000 shares through Schoodic Management BV, an entity he controls, indicating he retains a substantial overall stake in the company.
PHVS affiliate files Rule 144 notice to sell 2,292 shares of Common Stock appearing as Restricted Stock Units with an intended sale date of 04/11/2026. The filing also reports prior 10b5-1 sales of 23,333 shares on 04/08/2026 for $647,283.26.